However, a pivotal report from the Steven Rosenberg group has offered strong evidence for KRAS-directed immunotherapy: a patient with CRC exhibited clinically relevant remission upon infusion of tumor-infiltrating lymphocytes (TIL) targeting a mutant KRAS epitope (harboring the G12D mutation) restricted by HLA-C*w0802 (11). Here, HLA-C is linked to neoplasm.